Toboroz
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
NCT07576335· 2. fázis· Surgical Outcomes Research Centre (SOuRCe)· Forrás
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· 2. fázis· Verastem, Inc.· Forrás
Toboroz
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858· 2. fázis· Gilead Sciences· Forrás
Még nem toboroz
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
NCT07527819· Peter MacCallum Cancer Centre, Australia· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· 2. fázis· Genmab· Forrás
Toboroz
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT07235293· 2. fázis· Kahr Bio Australia Pty Ltd· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094· 3. fázis· Genmab· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845· 2. fázis· AbbVie· Forrás
Toboroz
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
PRIORITY-CONNECT 2 Trial
NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Forrás
Toboroz
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771· 2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197· 1. fázis· Dizal Pharmaceuticals· Forrás
Toboroz
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128· 1/2. fázis· Bayer· Forrás
Toboroz
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990· 2/3. fázis· Bicara Therapeutics· Forrás
Toboroz
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172· 1. fázis· Epkin· Forrás
Toboroz
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317· 3. fázis· ETOP IBCSG Partners Foundation· Forrás
Toboroz
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908· 2. fázis· Johnson & Johnson Enterprise Innovation Inc.· Forrás
Toboroz
A Study of DM005 in Patients With Advanced Solid Tumors
NCT06515990· 1/2. fázis· Doma Biopharmaceutical（Suzhou）Co., Ltd.· Forrás
Toboroz
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
NCT06441747· 2. fázis· Australasian Gastro-Intestinal Trials Group· Forrás
Toboroz
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
NCT07377747· Australia and New Zealand Sarcoma Association· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Toboroz
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06318273· 1. fázis· AbbVie· Forrás
Toboroz
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478· 2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481· 1. fázis· AbbVie· Forrás
Fut, nem toboroz
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931· 3. fázis· Karyopharm Therapeutics Inc· Forrás
Fut, nem toboroz
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· 3. fázis· Bayer· Forrás
Toboroz
Metastatic Leiomyosarcoma Biomarker Protocol
NCT05653388· University of Michigan Rogel Cancer Center· Forrás
Fut, nem toboroz
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984· 1. fázis· AbbVie· Forrás
Toboroz
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
NCT05393791· 2. fázis· Leiden University Medical Center· Forrás
Toboroz
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
NCT05025813· 2. fázis· Queensland Health· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789· 1/2. fázis· Nuvalent Inc.· Forrás
Fut, nem toboroz
A Study of AL102 in Patients With Progressing Desmoid Tumors
NCT04871282· 2/3. fázis· Immunome, Inc.· Forrás
Fut, nem toboroz
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398· 3. fázis· Akeso· Forrás
Toboroz
Personalised Immunotherapy Platform
NCT06536257· Melanoma Institute Australia· Forrás
Fut, nem toboroz
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004· 2. fázis· Daiichi Sankyo· Forrás
Showing 50 of 76.